Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood

Summary.  Background and objectives: Patients treated with percutaneous coronary intervention receive aspirin and P2Y12 ADP receptor inhibitors to reduce thrombotic complications. The choice of methodology for monitoring the effects of treatment and assessing its efficacy is still a topic of debate. We evaluated how decreased P2Y12 function influences platelet aggregate (thrombus) size measured ex vivo. Methods and results: We used confocal videomicroscopy to measure in real time the volume of platelet thrombi forming upon blood perfusion over fibrillar collagen type I at a wall shear rate of 1500 s−1. The average volume was significantly smaller in 31 patients receiving aspirin and clopidogrel (19) or ticlopidine (12) than in 21 controls, but individual values were above the lower limit of the normal distribution, albeit mostly within the lower quartile, in 61.3% of cases. Disaggregation of platelet thrombi at later perfusion times occurred frequently in the patients. Vasodilator‐stimulated phosphoprotein phosphorylation, reflecting P2Y12 inhibition, was also decreased in the patient group, and only 22.6% of individual values were above the lower normal limit. We found no correlation between volume of thrombus formed on collagen fibrils and level of P2Y12 inhibition, suggesting that additional and individually variable factors can influence the inhibitory effect of treatment on platelet function. Conclusions: Measurements of platelet thrombus formation in flowing blood reflects the consequences of antiplatelet therapy in a manner that is not proportional to P2Y12 inhibition. Combining the results of the two assays may improve the assessment of thrombotic risk.

[1]  P. Morange,et al.  Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. , 2010, Archives of cardiovascular diseases.

[2]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[3]  K. Kent,et al.  Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. , 2009, The American journal of cardiology.

[4]  N. Kleiman,et al.  Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. , 2009, The American journal of cardiology.

[5]  S. Srinivasan,et al.  The P2Y12 Antagonists, 2-Methylthioadenosine 5′-Monophosphate Triethylammonium Salt and Cangrelor (ARC69931MX), Can Inhibit Human Platelet Aggregation through a Gi-independent Increase in cAMP Levels* , 2009, The Journal of Biological Chemistry.

[6]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[7]  F. Santilli,et al.  Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". , 2009, Journal of the American College of Cardiology.

[8]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[9]  Z. Ruggeri,et al.  Platelet Adhesion under Flow , 2009, Microcirculation.

[10]  J. Hirsh,et al.  Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future , 2008, Nature Clinical Practice Cardiovascular Medicine.

[11]  M. Lordkipanidzé,et al.  Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. , 2008, European heart journal.

[12]  S. Goto,et al.  The challenge of monitoring platelet response after clopidogrel. , 2008, European Heart Journal.

[13]  B. Giusti,et al.  Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function , 2008, Thrombosis and Haemostasis.

[14]  A. Gori,et al.  Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[15]  Antiplatelet Therapy and Platelet Function Testing , 2008, Clinical cardiology.

[16]  R. Blindt,et al.  The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis , 2007, Thrombosis and Haemostasis.

[17]  P. Morange,et al.  ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome , 2007, Thrombosis and Haemostasis.

[18]  O. Morel,et al.  Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis , 2007, Thrombosis and Haemostasis.

[19]  J. Jukema,et al.  Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. , 2007, American heart journal.

[20]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[21]  S. Steinhubl,et al.  Optimizing platelet P2Y12 inhibition for patients undergoing PCI. , 2007, Cardiovascular drug reviews.

[22]  P. Gurbel,et al.  Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? , 2007, Journal of the American College of Cardiology.

[23]  S. Goto,et al.  Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. , 2006, Journal of the American College of Cardiology.

[24]  P. Gurbel,et al.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.

[25]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[26]  P. Théroux,et al.  Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. , 2005, Journal of the American College of Cardiology.

[27]  O. Hess,et al.  CLINICAL RESEARCH Interventional Cardiology Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy , 2005 .

[28]  J. Geiger,et al.  Monitoring of clopidogrel action: comparison of methods. , 2005, Clinical chemistry.

[29]  C. Gachet,et al.  Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases , 2005, Journal of thrombosis and haemostasis : JTH.

[30]  B. Jilma,et al.  Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA‐100 , 2004, Journal of thrombosis and haemostasis : JTH.

[31]  Mario Mazzucato,et al.  Distinct roles of ADP receptors in von Willebrand factor-mediated platelet signaling and activation under high flow. , 2004, Blood.

[32]  Z. Ruggeri,et al.  Signaling Through GP Ib-IX-V Activates αIIbβ3 Independently of Other Receptors , 2004 .

[33]  C. Watala,et al.  Limited usefulness of the PFA-100™ for the monitoring of ADP receptor antagonists–in vitro experience , 2004, Clinical chemistry and laboratory medicine.

[34]  P. Conley,et al.  Anticoagulants (Thrombin Inhibitors) and Aspirin Synergize With P2Y12 Receptor Antagonism in Thrombosis , 2003, Circulation.

[35]  P. Conley,et al.  P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. , 2003, The Journal of clinical investigation.

[36]  Zaverio M. Ruggeri,et al.  Platelets in atherothrombosis , 2002, Nature Medicine.

[37]  P. Nguyên,et al.  PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? , 2002, Thrombosis research.

[38]  J. Moake,et al.  Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. , 2001, Blood.

[39]  J. Seward,et al.  The effectiveness of the varicella vaccine. , 2001, The New England journal of medicine.

[40]  P. Conley,et al.  Impaired activation of murine platelets lacking Gαi2 , 2001 .

[41]  S. Goto,et al.  Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation , 2001, Platelets.

[42]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[43]  U. Walter,et al.  Flow Cytometry Analysis of Intracellular VASP Phosphorylation for the Assessment of Activating and Inhibitory Signal Transduction Pathways in Human Platelets , 1999, Thrombosis and Haemostasis.

[44]  Z. Ruggeri,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Contribution of Distinct Adhesive Interactions to Platelet Aggregation in Flowing Blood , 1999 .

[45]  Brian Savage,et al.  Specific Synergy of Multiple Substrate–Receptor Interactions in Platelet Thrombus Formation under Flow , 1998, Cell.

[46]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[47]  K. Titani,et al.  A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. , 1987, The Journal of biological chemistry.